Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0.
Context
- Depreciation & amortization increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Depreciation & Amortization vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 depreciation & amortization of $0 is the 7th highest of the 8 companies compared; the peer median is $148K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.43M | -42.2% | -13.8% | 33645.2% | |
| LTM Mar 2026 | $3.4M | — | — | 12.3% | |
| LTM Mar 2026 | $2.79M | -10.3% | +0.1% | 9.9% | |
| LTM Mar 2026 | $148K | -99.6% | -26.0% | 1.2% | |
| LTM Mar 2026 | $31K | -22.5% | -27.4% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $20K | — | — | — |
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding PLYX) | $148K | -42.2% | -19.9% | 11.1% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.